No Data
No Data
Express News | Oragenics : Onp-002 Expected to Have Large Cardiac Safety Margin, Suggesting Onp-002 Treatment for Concussion Will Not Cause Cardiac Arrhythmia
Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing
EXCLUSIVE: Oragenics' Concussion Drug Clears FDA-Required Cardiotoxicity Testing, Planning For Phase Trials Underway
Express News | EXCLUSIVE: Oragenics Tells Benzinga 'The Potential Addressable Market Opportunity for ONP-002 Includes an Estimated 69 Million Concussions Globally'
Express News | EXCLUSIVE: Oragenics Tells Benzinga Co. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing
Express News | Oragenics Shares Are Trading Higher After the Company Announced It Developed a New Formulation for Its Novel Neurosteroid
No Data